Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04311762 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Trial of Endobronchial Ultrasound-Guided Transbronchial Needle Injection of Cisplatin for Stage IV Lung Cancer
A Phase 1 study of Lung Cancer Metastatic, sponsored by University of Vermont.
- Active
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT04311762: Active Phase 1 study of Lung Cancer Metastatic, sponsored by University of Vermont.
NCT04311762 is a Phase 1 study of Lung Cancer Metastatic that is active but no longer recruiting, run by University of Vermont. The registered enrollment target is 16 participants, below the 366-participant average among 8 other Lung Cancer Metastatic trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04311762, a Phase 1 study of Lung Cancer Metastatic, is active but no longer recruiting, sponsored by University of Vermont.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of the study is to identify the maximum tolerated dose of endobronchial ultrasound-guided transbronchial injection (EBUS-TBNI) of cisplatin for Stage IV lung cancer.
Conditions Studied
Interventions
- DRUG cisplatin
Study Locations (1)
Vermont
- University of Vermont - Burlington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2020-02-01 |
| Est. Completion | 2029-03-01 |
| Phase | Phase 1 |
What the registry record for NCT04311762 still lists
NCT04311762 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 366-participant average among 8 other Lung Cancer Metastatic trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Lung Cancer Metastatic appearing as the primary indexed condition, and to 1 intervention - of which cisplatin is the first listed.
NCT04311762 reports a single indexed study location in Vermont.
Frequently Asked Questions
What is clinical trial NCT04311762 about?
NCT04311762 is a clinical study titled "Phase 1 Trial of Endobronchial Ultrasound-Guided Transbronchial Needle Injection of Cisplatin for Stage IV Lung Cancer". The goal of the study is to identify the maximum tolerated dose of endobronchial ultrasound-guided transbronchial injection (EBUS-TBNI) of cisplatin for Stage IV lung cancer.
What is the current status of trial NCT04311762?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2020-02-01. Estimated completion is 2029-03-01.
What conditions does trial NCT04311762 study?
This clinical trial studies the following conditions: Lung Cancer Metastatic.
What interventions are being tested in trial NCT04311762?
The interventions under investigation include: cisplatin (DRUG).
Who is sponsoring clinical trial NCT04311762?
This trial is sponsored by University of Vermont, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04311762 being conducted?
This trial has 1 study location across Vermont. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer Metastatic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04311762's enrollment target sits among peer trials
16 9th of 8 the lowest of 8 other Lung Cancer Metastatic trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Cancer Metastatic trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
RECRUITING · Phase 1
-
Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
RECRUITING · Phase 1
-
A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib
COMPLETED · Phase 1
-
I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy
RECRUITING
-
A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI